10-K: Ionis Pharmaceuticals Reports 2024 Results, Highlights Commercial Progress and Pipeline Advancements

Ionis Pharmaceuticals reports $705 million in revenue for 2024, marking a year of commercial expansion and pipeline progress.

Summary

• Ionis Pharmaceuticals reported total revenues of $705 million for the year 2024.
• The company ended 2024 with $2.3 billion in cash and short-term investments.
• Key achievements include the U.S. commercial launch of TRYNGOLZA and continued advancement of nine medicines in Phase 3 development.
• Eight positive data readouts were delivered from the lateand mid-stage pipeline.
• The company is positioning for its second independent commercial launch in 2025 with donidalorsen for hereditary angioedema.
• The company has six marketed medicines: TRYNGOLZA, WAINUA, SPINRAZA, QALSODY, TEGSEDI, and WAYLIVRA.
• TRYNGOLZA was approved by the FDA in December 2024 as the first-ever treatment for familial chylomicronemia syndrome (FCS).
• WAINUA is approved in the U.S., UK, and Canada for the treatment of polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN).
• SPINRAZA is a global market leader for the treatment of spinal muscular atrophy (SMA).
• QALSODY is approved in the U.S., EU, China, and Japan for the treatment of Amyotrophic Lateral Sclerosis (ALS) in adults with a SOD1 mutation.
• The company plans to advance ION582 into Phase 3 development in the first half of 2025 for Angelman syndrome (AS).

Sentiment

Score: 6

Explanation: The document presents a mixed sentiment. While there are positive developments such as new drug approvals and pipeline advancements, the financial results show a decrease in revenue and an increase in net loss, which tempers the overall outlook.

Positives

• FDA approval of TRYNGOLZA marks Ionis' first independent commercial launch.
• WAINUA is approved in multiple countries and co-commercialized with AstraZeneca in the U.S.
• Positive data readouts from the lateand mid-stage pipeline demonstrate continued innovation.
• Strong cash position of $2.3 billion enables continued investment in launches and development.
• Advancement of ION582 into Phase 3 development indicates progress in neurology.
• The company has a broad portfolio of partnered medicines in late-stage development.

Negatives

• Total revenue decreased from $787.6 million in 2023 to $705.1 million in 2024.
• Loss from operations increased from $(353.7) million in 2023 to $(475.1) million in 2024.
• Net loss increased from $(366.3) million in 2023 to $(453.9) million in 2024.
• SPINRAZA royalties decreased due to an annual order from a single country that did not recur in 2024.
• R&D revenue decreased due to the timing of significant partner payments.

Risks

• The company has limited experience as a company in commercializing medicines and will have to continue to invest significant resources to develop its capabilities.
• The market may not accept the company's medicines, including commercial medicines and medicines in development.
• The company may fail to compete effectively, and its medicines may not generate significant revenues.
• The company depends on collaborations with Biogen and AstraZeneca for the development and commercialization of SPINRAZA, QALSODY and WAINUA.
• The company may not be successful in expanding its manufacturing capabilities or cannot manufacture its medicines or contract with a third party to manufacture its medicines at costs that allow it to charge competitive prices to buyers.
• The company may fail to obtain regulatory approval for its medicines and additional approvals for its commercial medicines.
• The company may fail to obtain timely funding and may need to curtail or abandon some of its programs.
• The company has incurred losses, and its business will suffer if it fails to consistently achieve profitability in the future.
• The company may not be entitled to obtain additional milestone payments under its royalty monetization agreement with Royalty Pharma.
• The company may not be able to protect its patent rights or its other proprietary rights, and others may compete more effectively against it.
• The company is exposed to potential product liability claims, and insurance against these claims may not be available to it at a reasonable rate in the future or at all.
• The loss of key personnel, or the inability to attract and retain highly skilled personnel, could make it more difficult to run the company's business and reduce its likelihood of success.
• The company's business may be adversely affected by health epidemics, climate change, extreme weather events, fires, earthquakes, war, civil or political unrest, terrorism or other catastrophic events.
• The company is dependent on data as well as information technology systems and infrastructure, which exposes it to data protection risks.
• The increasing use of social media platforms and artificial intelligence based software presents new risks and challenges.
• If the company does not progress in its programs as anticipated, the price of its securities could decrease.
• If the price of the company's securities continues to be highly volatile, this could make it harder to liquidate your investment and could increase your risk of suffering a loss.
• Negative conditions in the global credit markets and financial services and other industries may adversely affect the company's business, financial condition or stock price.
• A variety of risks associated with operating the company's business and marketing its medicines internationally could adversely affect its business.
• Provisions in the company's certificate of incorporation, bylaws, convertible notes documents, call spread hedge transaction documents and Delaware law may prevent stockholders from receiving a premium for their shares.
• Future sales of the company's common stock in the public market could adversely affect the trading price of its securities.
• The company's operations are subject to extensive legal and regulatory requirements affecting the health care industry.
• Because the company uses biological materials, hazardous materials, chemicals and radioactive compounds, if it does not comply with laws regulating the protection of the environment and health and human safety, its business could be adversely affected.
• The company's business is subject to changing regulations for corporate governance and public disclosure that has increased both its costs and the risk of noncompliance.
• The company's ability to use its net operating loss carryovers and certain other tax attributes may be limited.
• The company's future taxable income could be impacted by changes in tax laws, regulations and treaties.
• The company could be subject to additional tax liabilities.

Future Outlook

Ionis is positioned to deliver multiple products to the market independently in the next three years and has a rich innovative lateand mid-stage pipeline.

Management Comments

• In the last year, we delivered on our strategy to create accelerating value for all our stakeholders.
• With our commercial launch of TRYNGOLZA (olezarsen) in the United States, or U.S., following its approval by the U.S. Food and Drug Administration, or FDA, we began a new chapter as a fully integrated commercial-stage biotechnology company.

Industry Context

The company competes with other pharmaceutical and biotechnology companies in the development and commercialization of genetic medicines and RNA-targeted therapies.

Comparison to Industry Standards

• Competitors for SPINRAZA include Novartis (Zolgensma) and Roche (Evrysdi).
• Competitors for WAINUA include Alnylam (Onpattro, Amvuttra) and Pfizer (Vyndaqel/Vyndamax).
• Competitors for donidalorsen include Takeda (Takhzyro, Cinryze) and BioCryst (Orladeyo).
• Competitors for pelacarsen include Amgen/Arrowhead (Olpasiran) and Lilly (Lepodisiran).
• Competitors for sefaxersen include Asahi Kasei (Tarpeyo) and Travere (Filspari).

Stakeholder Impact

• Shareholders: Impacted by financial performance and stock price volatility.
• Employees: Affected by company performance and potential changes in operations.
• Patients: Benefit from new medicines and advancements in treatment options.
• Partners: Impacted by the progress and success of collaborative programs.

Next Steps

• Advance ION582 into Phase 3 development in the first half of 2025.
• Await data from the ESSENCE study in mid-2025.
• Await data from the CORE and CORE2 studies in the second half of 2025.
• Await FDA decision on donidalorsen by August 21, 2025.

Key Dates